Why the study?
Does intracoronary abciximab improve safety outcomes in patients undergoing percutaneous coronary intervention?
Does intracoronary abciximab improve safety outcomes in patients undergoing percutaneous coronary intervention?
Intracoronary administration of abciximab during PCI appears safe and well-tolerated, with a very low complication rate in a single-operator community hospital setting.
Answers are grounded in this paper and cite their sources.
Supports limited safety data for intracoronary abciximab; leaves open its role in PCI and requires prospective trials.
OBJECTIVE: To evaluate the safety of intracoronary (IC) abciximab during percutaneous coronary intervention (PCI). BACKGROUND: Adjunctive treatment with glycoprotein IIb/IIIa inhibitors, especially abciximab, during PCI has been shown to improve clinical and procedural outcomes in numerous studies. However, significant bleeding complications exist with its use and this has limited its standard use. Interest has grown in local (IC) use with studies showing safety and long-term effectiveness, especially in patients with high thrombus loads. METHODS: A retrospective review of records in a database of patients who had PCI by a single operator at the Easton Hospital. RESULTS: 611 patients received IC abciximab, and there were no complications in 610 (98.3%) patients; only 1 had an allergic reaction. CONCLUSIONS: IC abciximab is safe and has a unique role in the catheterization lab and in patients at high risk of bleeding complications who would benefit from its limited use.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: